Corium International Inc. (NASDAQ:CORI) fell 2.3% during mid-day trading on Wednesday . The stock traded as low as $4.98 and last traded at $5.41, with a volume of 100,426 shares. The stock had previously closed at $5.29.

Several research firms recently issued reports on CORI. FBR & Co reissued a “buy” rating on shares of Corium International in a research report on Monday, May 2nd. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, July 19th. Jefferies Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Corium International in a research report on Wednesday, May 11th. WBB Securities raised shares of Corium International from a “hold” rating to a “speculative buy” rating and set a $11.00 price target on the stock in a research report on Tuesday, May 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Corium International in a research report on Thursday, June 23rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $11.92.

The stock’s market cap is $147.79 million. The company has a 50-day moving average price of $4.61 and a 200-day moving average price of $4.37.

Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. Equities analysts anticipate that Corium International Inc. will post ($1.63) EPS for the current year.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.